Greenbrook TMS completes US$13.2 million bought deal public offering

On September 27, 2021, Greenbrook TMS Inc. (the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, completed its previously-announced public offering. The offering was made pursuant to an underwriting agreement entered into among Stifel GMP, Bloom Burton Securities Inc. and Lake Street Capital Markets, LLC.

Pursuant to the offering, the Company issued a total of 1,707,750 common shares of the Company at a price of US$7.75 per common share for gross proceeds of approximately US$13.2 million, including 222,750 common shares issued pursuant to the full exercise of the underwriters’ over-allotment option.

The Company intends to use the net proceeds from the offering to fund its previously-announced acquisition of Achieve TMS East, LLC and Achieve TMS Central, LLC and for working capital and general corporate purposes.

Further information can be found on Business Wire’s website.

Greenbrook is a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States.